Skip to main content
. 2019 Jan 21;11(1):124. doi: 10.3390/cancers11010124
ALK anaplastic lymphoma kinase
NSCLC non-small cell lung cancer
TKI tyrosine kinase inhibitor
TNT
TP53
time-to-next-treatment
tumor protein p53
PFS progression-free survival
OS overall survival